Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Do cystic fibrosis patients have hidden COVID protection?

NCT ID NCT05614336

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether people with cystic fibrosis (CF) have COVID-19 antibodies in their blood over two years. Researchers wanted to see if CF patients get infected less often or have milder symptoms. About 331 children and adults with CF from Europe gave blood samples and shared health information. The goal was to learn more about how COVID-19 affects people with CF, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

331 people

The number who actually took part.

Started

Jun 2022

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Person with cystic fibrosis of any age, genotype, transplant status and disease severity. * Express consent obtained after informing the patient and/or his legal representatives or parents In France, written and informed consent will be requested. * For France, affiliation to a social security scheme or similar Exclusion Criteria: * Refusal to give informed consent * Contraindication to venepuncture * For France * Person under guardianship / curatorship * Person under legal protection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID -19 Cystic fibrosis

Contacts and locations

Locations

  • C.R.C.M. Pédiatrique (Centre de Ressources et de Compétences en Mucoviscidose) Hôpital des Enfants-Pellegrin - CHU de Bordeaux

    Bordeaux, 33076, France

  • CHU Timone-Enfants - APHM

    Marseille, France

  • CHU de Nice

    Nice, 06002, France

  • CRCM Pédiatrique Hôpital Sud - CHU de Rennes

    Rennes, 35203, France

  • Centre de Ressources et de Competences de la Mucoviscidose (Enfants) CHU Grenoble Alpes - Hôpital Couple Enfant

    Grenoble, 38043, France

  • Fondation Ildys

    Roscoff, 29684, France

  • Hôpital Albert Calmette - CHU de Lille

    Lille, France

  • Hôpital Cochin, AP-HP

    Paris, France

  • Hôpital Jeanne de Flandre

    Lille, France

  • Hôpital Necker Enfants Malades - APHP

    Paris, France

  • Hôpital Robert Debré - APHP

    Paris, France

  • Hôpitaux Pédiatriques de Nice CHU Lenval

    Nice, 06200, France

  • Maladies respiratoires, allergologie - CRCM Mixte de Rouen Hôpital Charles Nicole - CHU de Rouen

    Rouen, 76000, France

  • Pneumologie, allergologie et Mucoviscidose - CRCM Lyon pédiatrie Hôpital Femme Mère Enfant /Groupement Est

    Bron, 69677, France

  • Service Pneumologie-Allergologie CRCM adulte Hôpital Larrey - CHU de Toulouse

    Toulouse, 31059, France

  • Service de pneumo-allergologie pédiatrique CRCM pédiatrique CHU de Toulouse - Hôpital des Enfants

    Toulouse, 31059, France

  • Service de pneumologie - Centre cardio-pneumologie Hôpital Pontchaillou - CHU de Rennes

    Rennes, 35033, France

  • Service de pédiatrie générale et spécialisée American Memorial Hospital - CHU de Reims

    Reims, 51092, France

  • Service des maladies respiratoires Hôpital Arnaud de Villeneuve - CHU de Montpellier

    Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.